BioNTech’s Strategic Acquisition Nears Critical Deadline

BioNTech US09075V1026

The European biotech landscape is poised for a significant transformation as BioNTech approaches the final stages of its planned acquisition of CureVac. With shareholder approval secured, attention now shifts to the December 3, 2025 deadline that will determine whether this consolidation of German mRNA developers proceeds.

During Tuesday’s extraordinary general meeting, CureVac investors demonstrated near-unanimous backing for the proposed share exchange. An impressive 99.16 percent of voting shareholders approved the necessary resolutions, indicating strong investor confidence in combining these two pioneering mRNA technology firms.

Key transaction details include:

• Offer expiration: December 3, 2025, 3:00 PM CET
• Recommended submission deadline: December 2, 24:00 CET
• Exchange Read more...